Skip to main content

Advertisement

SpringerLink
Log in

Ki-67 labeling index and expression of p53 are non-predictive for invasiveness and tumor size in functional and nonfunctional pituitary adenomas

  • Original Article - Pituitaries
  • Published:
Acta Neurochirurgica Aims and scope Submit manuscript

Abstract

Background

It is still controversial whether an increased proliferation index is correlated with the tumor invasiveness of pituitary adenomas. A homogeneous large monocentric series of pituitary adenomas was retrospectively analyzed. The correlation between the proliferation indices (Ki-67 and p53 expression levels) and invasiveness and size of pituitary adenomas was investigated in primary operated and recurrent adenomas.

Method

Four hundred thirty-nine patients after resection of pituitary adenomas were retrospectively included (43 recurrent tumors, 196 null cell adenomas, 86 somatotroph adenomas, 55 corticotroph adenomas, 55 prolactinomas, 4 thyreotroph adenomas). The maximum tumor diameter and tumor invasiveness in Knosp grading were assessed and Ki-67 and p53 immunostaining was performed. The role of invasiveness was evaluated using a cumulative odds ordinal logistic regression. For calculating the effect of tumor size, a one-way analysis of variance (ANOVA) was conducted.

Results

Overall and in the subgroups, no significant correlation between proliferation indices and mean tumor diameter was found. No significant predictive expression value of Ki-67 and p53 on tumor invasiveness and in recurrent tumors could be demonstrated. There was a tendency that Ki-67 LI and p53 LI are higher in recurrent corticotroph adenomas and lactotroph adenomas but values did not reach the significant level.

Conclusion

Invasive character of pituitary adenomas is neither correlated with increased Ki-67 LI nor with increased p53 expression. Proliferation parameters are independent from adenoma size at initial presentation. The partly elevated expression of Ki-67 in recurrent tumors underlines the clinical importance of the marker.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Abe T, Sanno N, Osamura YR, Matsumoto K (1997) Proliferative potential in pituitary adenomas: measurement by monoclonal antibody MIB-1. Acta Neurochir 139:613–618

    Article  CAS  PubMed  Google Scholar 

  2. Chacko G, Chacko AG, Kovacs K, Scheithauer BW, Mani S, Muliyil JP, Seshadri MS (2010) The clinical significance of MIB-1 labeling index in pituitary adenomas. Pituitary 13:337–344. https://doi.org/10.1007/s11102-010-0242-7

    Article  PubMed  Google Scholar 

  3. Chiloiro S, Bianchi A, Doglietto F, de Waure C, Giampietro A, Fusco A, Iacovazzo D, Tartaglione L, Di Nardo F, Signorelli F, Lauriola L, Anile C, Rindi G, Maira G, Pontecorvi A, De Marinis L (2014) Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review. Pituitary 17:267–276. https://doi.org/10.1007/s11102-013-0500-6

    Article  PubMed  Google Scholar 

  4. Chiloiro S, Doglietto F, Trapasso B, Iacovazzo D, Giampietro A, Di Nardo F, de Waure C, Lauriola L, Mangiola A, Anile C, Maira G, De Marinis L, Bianchi A (2015) Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis. Neuroendocrinology 101:143–150. https://doi.org/10.1159/000375448

    Article  CAS  PubMed  Google Scholar 

  5. Cooper O (2015) Silent corticotroph adenomas. Pituitary 18:225–231. https://doi.org/10.1007/s11102-014-0624-3

    Article  PubMed  PubMed Central  Google Scholar 

  6. de Aguiar PH, Aires R, Laws ER, Isolan GR, Logullo A, Patil C, Katznelson L (2010) Labeling index in pituitary adenomas evaluated by means of MIB-1: is there a prognostic role? A critical review. Neurol Res 32:1060–1071. https://doi.org/10.1179/016164110X12670144737855

    Article  PubMed  Google Scholar 

  7. De Lellis RALR, Heitz PU et al (2004) World Health Organization classification of tumours: pathology and genetics of tumours of endocrine organs. IARC Press, Lyon, pp 9–47

    Google Scholar 

  8. Gejman R, Swearingen B, Hedley-Whyte ET (2008) Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Hum Pathol 39:758–766. https://doi.org/10.1016/j.humpath.2007.10.004

    Article  CAS  PubMed  Google Scholar 

  9. Honegger J, Prettin C, Feuerhake F, Petrick M, Schulte-Monting J, Reincke M (2003) Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness. J Neurosurg 99:674–679. https://doi.org/10.3171/jns.2003.99.4.0674

    Article  PubMed  Google Scholar 

  10. Iuchi T, Saeki N, Osato K, Yamaura A (2000) Proliferation, vascular endothelial growth factor expression and cavernous sinus invasion in growth hormone secreting pituitary adenomas. Acta Neurochir 142:1345–1351

    Article  CAS  PubMed  Google Scholar 

  11. Jahangiri A, Wagner JR, Pekmezci M, Hiniker A, Chang EF, Kunwar S, Blevins L, Aghi MK (2013) A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas. Neurosurgery 73:8–17discussion 17-18. https://doi.org/10.1227/01.neu.0000429858.96652.1e

    Article  PubMed  Google Scholar 

  12. Knosp E, Kitz K, Perneczky A (1989) Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67. Neurosurgery 25:927–930

    Article  CAS  PubMed  Google Scholar 

  13. Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33:610–617 discussion 617-618

    CAS  Google Scholar 

  14. Lee EH, Kim KH, Kwon JH, Kim HD, Kim YZ (2014) Results of immunohistochemical staining of cell-cycle regulators: the prediction of recurrence of functioning pituitary adenoma. World Neurosurg 81:563–575. https://doi.org/10.1016/j.wneu.2013.09.035

    Article  PubMed  Google Scholar 

  15. Lloyd RVOR, Kloppel G, Rosai J (2017) WHO classification of tumours of endocrine organs, 4th edn. IARC Press, Lyon, p 13

    Google Scholar 

  16. Madsen H, Borges TM, Knox AJ, Michaelis KA, Xu M, Lillehei KO, Wierman ME, Kleinschmidt-DeMasters BK (2011) Giant pituitary adenomas: pathologic-radiographic correlations and lack of role for p53 and MIB-1 labeling. Am J Surg Pathol 35:1204–1213. https://doi.org/10.1097/PAS.0b013e31821e8c96

    Article  PubMed  Google Scholar 

  17. Mastronardi L, Guiducci A, Spera C, Puzzilli F, Liberati F, Maira G (1999) Ki-67 labelling index and invasiveness among anterior pituitary adenomas: analysis of 103 cases using the MIB-1 monoclonal antibody. J Clin Pathol 52:107–111

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Matsuyama J (2012) Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables. Neurol Med Chir (Tokyo) 52:563–569

    Article  Google Scholar 

  19. Mete O, Gomez-Hernandez K, Kucharczyk W, Ridout R, Zadeh G, Gentili F, Ezzat S, Asa SL (2016) Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas. Mod Pathol 29:131–142. https://doi.org/10.1038/modpathol.2015.151

    Article  CAS  PubMed  Google Scholar 

  20. Miermeister CP, Petersenn S, Buchfelder M, Fahlbusch R, Ludecke DK, Holsken A, Bergmann M, Knappe HU, Hans VH, Flitsch J, Saeger W, Buslei R (2015) Histological criteria for atypical pituitary adenomas - data from the German pituitary adenoma registry suggests modifications. Acta Neuropathol Commun 3:50. https://doi.org/10.1186/s40478-015-0229-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Paek KI, Kim SH, Song SH, Choi SW, Koh HS, Youm JY, Kim Y (2005) Clinical significance of Ki-67 labeling index in pituitary macroadenoma. J Korean Med Sci 20:489–494. https://doi.org/10.3346/jkms.2005.20.3.489

    Article  PubMed  PubMed Central  Google Scholar 

  22. Ramirez C, Cheng S, Vargas G, Asa SL, Ezzat S, Gonzalez B, Cabrera L, Guinto G, Mercado M (2012) Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. J Clin Endocrinol Metab 97:1745–1751. https://doi.org/10.1210/jc.2011-3163

    Article  CAS  PubMed  Google Scholar 

  23. Righi A, Agati P, Sisto A, Frank G, Faustini-Fustini M, Agati R, Mazzatenta D, Farnedi A, Menetti F, Marucci G, Foschini MP (2012) A classification tree approach for pituitary adenomas. Hum Pathol 43:1627–1637. https://doi.org/10.1016/j.humpath.2011.12.003

    Article  CAS  PubMed  Google Scholar 

  24. Saeger W, Ludecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S (2007) Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 156:203–216. https://doi.org/10.1530/eje.1.02326

    Article  CAS  PubMed  Google Scholar 

  25. Saeger W, Honegger J, Theodoropoulou M, Knappe UJ, Schofl C, Petersenn S, Buslei R (2016) Clinical impact of the current WHO classification of pituitary adenomas. Endocr Pathol 27:104–114. https://doi.org/10.1007/s12022-016-9418-7

    Article  CAS  PubMed  Google Scholar 

  26. Salehi F, Agur A, Scheithauer BW, Kovacs K, Lloyd RV, Cusimano M (2009) Ki-67 in pituitary neoplasms: a review--part I. Neurosurgery 65:429–437discussion 437. https://doi.org/10.1227/01.NEU.0000349930.66434.82

    Article  PubMed  Google Scholar 

  27. Sarkar S, Chacko AG, Chacko G (2014) An analysis of granulation patterns, MIB-1 proliferation indices and p53 expression in 101 patients with acromegaly. Acta Neurochir 156:2221–2230discussion 2230. https://doi.org/10.1007/s00701-014-2230-6

    Article  PubMed  Google Scholar 

  28. Solarski M, Rotondo F, Syro LV, Cusimano MD, Kovacs K (2017) Alpha subunit in clinically non-functioning pituitary adenomas: an immunohistochemical study. Pathol Res Pract 213:1130–1133. https://doi.org/10.1016/j.prp.2017.07.010

    Article  CAS  PubMed  Google Scholar 

  29. Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, Bonneville JF, Assaker R, Auger C, Brue T, Cornelius A, Dufour H, Jouanneau E, Francois P, Galland F, Mougel F, Chapuis F, Villeneuve L, Maurage CA, Figarella-Branger D, Raverot G, members of H, Barlier A, Bernier M, Bonnet F, Borson-Chazot F, Brassier G, Caulet-Maugendre S, Chabre O, Chanson P, Cottier JF, Delemer B, Delgrange E, Di Tommaso L, Eimer S, Gaillard S, Jan M, Girard JJ, Lapras V, Loiseau H, Passagia JG, Patey M, Penfornis A, Poirier JY, Perrin G, Tabarin A (2013) A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126:123–135. https://doi.org/10.1007/s00401-013-1084-y

    Article  PubMed  Google Scholar 

  30. Warnet A, Porsova-Dutoit I, Lahlou N, Seret-Begue D, Lajeunie E, Chanson P, Woimant F, Lot G, Guillausseau PJ, Roger M (1994) Glycoprotein hormone alpha-subunit secretion in prolactinomas and in non-functioning adenomas: relation with the tumour size. Clin Endocrinol 41:177–184

    Article  CAS  Google Scholar 

  31. Zada G, Du R, Laws ER Jr (2011) Defining the “edge of the envelope”: patient selection in treating complex sellar-based neoplasms via transsphenoidal versus open craniotomy. J Neurosurg 114:286–300. https://doi.org/10.3171/2010.8.JNS10520

    Article  PubMed  Google Scholar 

  32. Zada G, Woodmansee WW, Ramkissoon S, Amadio J, Nose V, Laws ER Jr (2011) Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg 114:336–344. https://doi.org/10.3171/2010.8.JNS10290

    Article  PubMed  Google Scholar 

  33. Zaidi HA, Cote DJ, Dunn IF, Laws ER Jr (2016) Predictors of aggressive clinical phenotype among immunohistochemically confirmed atypical adenomas. J Clin Neurosci 34:246–251. https://doi.org/10.1016/j.jocn.2016.09.014

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department for Neurosurgery, University Hospital Tübingen, Hoppe-Seyler-Strasse 3, 72076, Tübingen, Germany

    Florian Grimm, Roland Maurus, Georgios Naros, Milan Stanojevic, Isabel Gugel, Sabrina Giese & Jürgen Honegger

  2. Institute of Pathology and Neuropathology, Department of Neuropathology, University Hospital Tübingen, Hoppe-Seyler-Strasse 3, 72076, Tübingen, Germany

    Rudi Beschorner

  3. Department for Neuroradiology, University Hospital Tübingen, Hoppe-Seyler-Strasse 3, 72076, Tübingen, Germany

    Georg Bier & Benjamin Bender

Authors
  1. Florian Grimm
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roland Maurus
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rudi Beschorner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Georgios Naros
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Milan Stanojevic
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Isabel Gugel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sabrina Giese
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Georg Bier
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Benjamin Bender
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jürgen Honegger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Florian Grimm.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (University Hospital Tübingen, Germany) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

For this type of study, formal consent is not required.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Pituitaries

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grimm, F., Maurus, R., Beschorner, R. et al. Ki-67 labeling index and expression of p53 are non-predictive for invasiveness and tumor size in functional and nonfunctional pituitary adenomas. Acta Neurochir 161, 1149–1156 (2019). https://doi.org/10.1007/s00701-019-03879-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00701-019-03879-4

Keywords

Search

Navigation